Promycin

Promycin®

Porfiromycin Oncology An orphan drug used to manage hypoxic CA cells, which are less susceptible to RT than other tumor cells. See Orphan drug, Radiation therapy.
References in periodicals archive ?
Research and development expenses for the first nine months of 2000 were $8,307,359, compared with expenses of $8,517,035, reported in the first nine months of 1999, reflecting increased preclinical activities related to the company's Sulfonyl Hydrazine technology, and patient enrollment for the Phase I human clinical trial of TAPET, offset by lower expenses under Vion's revised collaboration agreement with BI for the development of Promycin.
Central to its strategy to partner on development and commercialization of its products, VION has partnered with Boehringer Ingelheim on Promycin.
This decrease reflects the elimination of revenues from reimbursed development costs under the revised terms of Vion's collaboration agreement with BI for the development of Promycin, which was restructured in December 1999.
At the same time, accrual into additional clinical studies with Promycin sponsored by BI has been put on hold.
Note to Editors: Promycin and TAPET are registered trademarks of Vion Pharmaceuticals Inc.
Promycin, which attacks oxygen depleted cancer cells, is currently being evaluated with radiation in a multicenter Phase III clinical trial for the treatment of head and neck cancer.
Research and development expenses for the third quarter of 1996 totaled $974,569 compared to $1,423,736 in the previous quarter, due to reduced production expenses of clinical materials for expanded Phase III clinical testing of Promycin(TM) (porfiromycin), the reclassification of a previously expensed down payment for Phase III clinical testing of Promycin, and lower research support expenses at the Microfab Biosystems subsidiary for the quarter.
Promycin, which attacks oxygen deficient cancer cells, is currently being evaluated with radiation in a multicenter Phase III clinical trial for the treatment of head and neck cancer.
The company's anticancer agent, Promycin, is currently in Phase III clinical trials.
Promycin is a bioreductive alkylating agent being tested as an adjunct to radiation therapy in head and neck cancer patients.
multicenter Phase III trials of Promycin, and allows Vion to
Promycin received Orphan Drug Status for head and neck and cervical cancer from the FDA in 1996 and 1997, respectively.